Xiaoqing Liu
0009-0004-4457-0926
Publication & Citation Trends
Most Cited Works
Publications
96 total
Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial PDF
Cited by 48
OpenAlex
Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety From a Phase 2 Study in People’s Republic of China
Cited by 33
OpenAlex
Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial PDF
Cited by 92
OpenAlex
Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA Sequencing PDF
Cited by 43
OpenAlex
Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050) PDF
Cited by 38
OpenAlex
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial
Cited by 251
OpenAlex
A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer
Cited by 74
OpenAlex
Research Topics
Lung Cancer Treatments and Mutations
(64)
Lung Cancer Research Studies
(31)
Lung Cancer Diagnosis and Treatment
(18)
Colorectal Cancer Treatments and Studies
(14)
Gastric Cancer Management and Outcomes
(13)
Frequent Co-Authors
Affiliations
Hebei Medical University
National Council for Scientific and Technological Development
Anhui University
Army Medical University
Sun Yat-sen University